Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SE175
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
SE175 is an experimental organic nitrate vasodilator engineered as a nitric oxide (NO) donor with improved stability and reductive NO-release characteristics compared with traditional nitrates such as nitroglycerin and isosorbide dinitrate. It belongs to the same pharmacologic class as nitroglycerin, causing vascular smooth muscle relaxation via NO-mediated increases in cyclic guanosine monophosphate (cGMP), and has been investigated as a positive-control vasodilator in vascular and ocular models, as well as for encapsulation in peptide- or liposome-based nanocarriers for targeted delivery in placental and cerebral vascular disorders.[1][7][9][2][8]
Beyond the preview
Go deeper on SE175.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SE175.